We recently published a list of the 11 Best Australian Stocks to Buy According to Analysts. In this article, we are going to ...

Many investors are still learning about the various metrics that can be useful when analysing a stock. This article ...

Telix Pharmaceuticals excels in radiopharmaceuticals, with strong revenue growth driven by imaging products like Illuccix.

Telix CEO Christian Behrenbruch hinted changes to the US Food and Drug Administration have hampered approval of its new brain cancer imaging agent.

Telix Pharmaceuticals Limited’s TLX share price has dipped by 7.55%, which has investors questioning if this is right time to buy.

MELBOURNE, Australia and INDIANAPOLIS, May 13, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, ...

US President Donald Trump has signed an executive order aimed at reducing drug costs for Americans, by up to 80% immediately.

New approval provides French hospitals and clinics with access to a proven PSMA-PET imaging agentMELBOURNE, Australia, April 29, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX ...

TLX101 plus radiation showed 12.4-month median overall survival vs. 9.9 months with radiation alone. No serious adverse events were reported in the IPAX-Linz study. Get prepared for the Fed’s ...

MELBOURNE, Australia and INDIANAPOLIS, May 8, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, ...

MELBOURNE, Australia, May 5, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces that its prostate cancer PET [1] imaging agent ...

MELBOURNE, Australia and INDIANAPOLIS, May 08, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces that its Fibroblast Activation ...